Omalizumab yielded a high response rate and had an acceptable safety profile in children with chronic spontaneous urticaria (CSU), including those younger than 12 years, a meta-analysis showed.

The U.S. Food and Drug Administration has approved Xolair (omalizumab) to treat chronic idiopathic urticaria, a form of chronic hives, according to a news release. Xolair, co-developed and co-promoted ...

Please provide your email address to receive an email when new articles are posted on . Both guidelines begin with antihistamines. Guidelines in the US recommend further antihistamine use before ...

The presence of a positive chronic urticaria index, low blood histamine content, or both low immunoglobulin (Ig) E content and low blood histamine content in patients with chronic spontaneous ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...

Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...

ZURICH (Reuters) - Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

ATLANTA - If you have to be vigilant about what you eat, and keep an EpiPen close, Dr. Tom Chacko of Chacko Allergy, Asthma and Sinus Center, says the newly FDA-authorized allergy medication, Xolair, ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...